We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Early Disease Detection Made Easier with Aptamer-Related Blood Test

By LabMedica International staff writers
Posted on 01 Jan 2018
A novel, highly sensitive blood test for a wide range of serum proteins combines aptamer-DNA capture molecules with nanopore-based single molecule sensing.

Nucleic acid aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, nucleic acids, and even cells, tissues, and organisms. More...
Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications. Relative to monoclonal antibodies, DNA aptamers are small, stable, and non-immunogenic.

Investigators at Imperial College London (United Kingdom) recently described a fully flexible, scalable, and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific aptamer sequences along the backbone of a double-stranded DNA carrier.

Protein bound to the aptamer produced unique ionic current signatures, which facilitated accurate target recognition. This powerful approach enabled the investigators to differentiate individual protein sizes via characteristic changes in the sub-peak current. By using DNA carriers it was possible to perform single-molecule screening in human serum at ultra-low protein concentrations.

The investigators pointed out that the system could be expanded to more than five different aptamers, allowing simultaneous detection of multiple biomarkers. Furthermore, since the biomarkers were detected in human serum, preparation time was minimized and was less costly than traditional tests to detect these proteins.

Contributing author Dr. Alex Ivanov, research fellow in the department of chemistry at Imperial College London, said, "The detection of single molecules of biomarkers represents the ultimate in sensitivity for early diagnosis. We have now shown that this is possible to perform such measurements in real human samples, opening up the potential for meaningful early diagnosis."

The aptamer-based nanopore analytical method was described in the November 16, 2017, online edition of the journal Nature Communications.

Related Links:
Imperial College London


New
Gold Member
Aspiration System
VACUSAFE
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
POC Immunoassay Analyzer
Procise DX
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: The researchers derived a gene-based signature and a blood test to help identify this high-risk subgroup (photo credit: Shutterstock)

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.